Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

Annals of Pediatric Endocrinology & Metabolism, published by the Korean Society of Pediatric Endocrinology, is a vital resource for researchers, healthcare professionals, and students in the fields of endocrinology, diabetes, and pediatric health. With its commitment to open access since 2012, the journal facilitates the dissemination of groundbreaking research on pediatric endocrine disorders and metabolic diseases, ensuring that vital knowledge is accessible to a global audience. The journal maintains a reputable standing with a 2023 Scopus rank of #92 in Pediatrics and a Q3 quartile in Endocrinology, highlighting its impact on the field. Originating from South Korea, the journal fosters a collaborative network of researchers and advocates best practices in pediatric care through interdisciplinary studies. The Annals not only enhances scientific understanding but also emphasizes practical applications aimed at improving child health outcomes, making it an essential publication for academics and practitioners alike.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

Hormone Molecular Biology and Clinical Investigation, published by WALTER DE GRUYTER GMBH, is a pivotal journal within the realms of Endocrinology, Diabetes and Metabolism, and Molecular Biology, contributing significant insights to the field since its inception in 2010. With an ISSN of 1868-1883 and an E-ISSN of 1868-1891, this esteemed journal operates from its headquarters in Berlin, Germany. As a further testament to its growing influence, the journal has achieved respectable category quartile rankings in 2023, including Q3 in Endocrinology, Diabetes and Metabolism and Medicine (miscellaneous), alongside Q4 in Molecular Biology. While currently not open access, the journal is dedicated to disseminating high-quality research aimed at understanding hormone-related mechanisms, clinical applications, and the biochemical pathways that underpin human health. The rich variety of articles published in Hormone Molecular Biology and Clinical Investigation make it an invaluable resource for researchers, medical professionals, and students seeking to deepen their knowledge in these critical scientific areas.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

Minerva Endocrinology, published by EDIZIONI MINERVA MEDICA in Italy, serves as a pivotal platform for advancing knowledge in the field of endocrinology, diabetes, and metabolism. With its ISSN 2724-6507 and E-ISSN 2724-6116, the journal has rapidly established a reputable position in academia, achieving impressive rankings such as Q3 in both Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. This enables Minerva Endocrinology to attract a diverse readership, including researchers, healthcare professionals, and students committed to understanding the complexities of endocrine disorders. With annual publications covering breakthroughs and innovative research covering converged years from 2021 to 2024, the journal is devoted to facilitating the dissemination of high-quality studies that advance clinical and laboratory practices. Despite its >Open Access< status, the journal encourages submissions that reflect rigorous scientific inquiry and uphold the highest standards of scholarship, thereby enhancing its role as a significant contributor to the field of internal medicine and endocrinology.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, published by SPRINGER, is a leading peer-reviewed journal dedicated to advancing the field of endocrinology. With a remarkable history dating back to 1978 and a convergence set until 2024, this journal serves as a vital source for researchers, clinicians, and students focusing on the intricate interplay of hormonal regulation and its implications for health and disease. The journal is recognized in the Q2 category for both Endocrinology and Endocrinology, Diabetes and Metabolism, highlighting its relevance and impact within the scientific community, exemplified by its strong Scopus rankings. While it does not offer open access, it ensures that high-quality research, reviews, and significant clinical findings are accessible to its readership. With a commitment to improving patient outcomes and elucidating complex biological mechanisms, the JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION remains a cornerstone publication for anyone involved in the study or practice of endocrinology.

The International Journal of Endocrinology and Metabolism is a leading peer-reviewed publication dedicated to advancing knowledge and research in the fields of endocrinology, diabetes, and metabolism. Published by BRIEFLAND in the Netherlands, this journal features original research, comprehensive reviews, and insightful clinical studies that explore the multifaceted aspects of hormonal disorders and metabolic conditions. With an impact factor that places it in the Q3 quartile category for 2023, the journal serves as a critical resource for academics and practitioners aiming to stay at the forefront of this dynamic field. Spanning from 2010 to 2024, the journal offers an enriching platform for innovative ideas and practices, fostering collaboration among scholars and healthcare professionals alike. Although not open access, the content is meticulously curated to ensure high-quality scientific discourse, positioning the International Journal of Endocrinology and Metabolism as an essential reference for those dedicated to improving health outcomes related to endocrine and metabolic disorders.

Lancet Diabetes & Endocrinology is a premier peer-reviewed journal, published by Elsevier Science Inc, dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Established in 2013, this journal has quickly ascended to a position of notable prestige, reflected in its prestigious Q1 rank across various categories, including Endocrinology, Internal Medicine, and Diabetes & Metabolism. With an impressive impact factor and Scopus rankings placing it in the 99th percentile of its field, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal aims to disseminate high-quality research covering clinical and experimental aspects of metabolic and endocrine disorders, making it an indispensable tool for those looking to stay at the forefront of these rapidly evolving fields. With its focus on innovative depth and cutting-edge studies, Lancet Diabetes & Endocrinology continually fosters an international dialogue critical for advancements in diabetes and endocrinology.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES is a distinguished journal published by GEORG THIEME VERLAG KG, dedicated to advancing research and understanding in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 0947-7349 and an E-ISSN of 1439-3646, this journal serves as a critical platform for disseminating high-quality research findings, reviews, and clinical studies from 1983 to 2024. The journal holds an impactful position within its respective categories, notably achieving Q3 in Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as per the 2023 category quartiles. Additionally, it ranks in the 57th and 46th percentiles in the Scopus rankings for Internal Medicine and Endocrinology, Diabetes and Metabolism, respectively. Though not an open-access publication, the journal caters to a global audience of researchers, professionals, and students, facilitating knowledge exchange and fostering collaboration within this vital area of medical science.